Glucagon-like peptide-1 (GLP-1) receptor agonists are still being described primarily by what they do to the bathroom scale. What they appear to do to the heart and kidneys is already changing clinical thinking. 

The Synthesis: Semaglutide, the active ingredient behind drugs such as Ozempic and Wegovy, entered public consciousness as a weight-loss treatment. The evidence has accumulated into something considerably more complex. The SELECT trial, a randomised controlled trial in the New England Journal of Medicine enrolling more than 17,000 adults with obesity and established cardiovascular disease but without diabetes, compared semaglutide against placebo over three years. Major cardiovascular events occurred in 6.5% of the semaglutide group versus 8.0% on placebo, a relative reduction of approximately 20%, or roughly 1.5 fewer events per 100 people over the trial period. The benefit appeared regardless of how much weight participants lost, suggesting mechanisms beyond caloric reduction, plausibly including direct anti-inflammatory and cardiac effects.

A second major trial, the FLOW study in the New England Journal of Medicine, tested semaglutide in people with type 2 diabetes and chronic kidney disease. Among those on semaglutide, roughly 19% experienced kidney failure, a sustained decline in kidney function, or cardiovascular death over three years, compared with 25% on placebo, a relative reduction of 24% in a population that has historically had few effective options.

The Calibration: Public framing of these drugs remains anchored to weight loss, and the surrounding discourse remains focused on shortages, cosmetic applications, and affordability. For people with established cardiovascular disease or chronic kidney disease, semaglutide now rests on multiple large outcome trials showing benefits that extend beyond weight loss alone. The miscalibration is not that semaglutide is overhyped, but that the dominant public conversation continues to track a narrower story than the evidence now supports.

The Synthesis: A prospective cohort analysis published in the Journal of the American College of Cardiology: Advances followed around 6,000 adults in the United States aged 45 to 84 without existing cardiovascular disease, drawn from the Multiethnic Study of Atherosclerosis. Over 13 years, 710 cardiovascular events occurred. Compared with those in the lowest fifth of ultraprocessed food consumption, those in the highest fifth had a 66.8% higher relative risk, which in absolute terms represents roughly 6 events per 100 people in the lowest-consumption group versus approximately 10 per 100 in the highest. This is an observational study and cannot establish causation; heavy ultraprocessed food consumers differ from lighter consumers in many health-relevant ways.

The Calibration: The evidence linking ultraprocessed food to cardiovascular harm is large, consistent across diverse populations, and biologically plausible. Mechanistic research has identified excess sodium, refined carbohydrates, and certain additives as likely contributors to inflammation and metabolic dysfunction. At the same time, observational nutrition research faces structural limitations no single study overcomes: dietary assessment is imprecise, and ultraprocessed food intake correlates with dozens of other lifestyle and socioeconomic variables. What the literature supports is a general direction. What it cannot reliably deliver is the numerical precision that individual study headlines typically imply.

The Synthesis: Sleep duration is among the most consistently supported modifiable risk factors for dementia, yet public understanding of the evidence remains unsteady, prone to both overstatement and dismissal. A cohort study published in Nature Communications followed approximately 8,000 British civil servants over 25 years. It found that those consistently sleeping six hours or fewer per night in their fifties had approximately 30% higher risk of developing dementia compared to those sleeping seven hours, translating from roughly 8 in 100 to approximately 10.5 in 100 over the follow-up period. Sleep supports activity of the brain's glymphatic clearance system, which helps remove amyloid-beta and tau proteins. This provides one biologically plausible explanation for the observed association between chronic short sleep and dementia. Furthermore, consistently long sleep, above nine hours, is also associated with elevated dementia risk in multiple studies, though this likely reflects underlying neurological changes rather than a causal effect.

The Calibration: The evidence is predominantly observational, and reverse causality is a genuine possibility: people with early neurodegeneration may sleep poorly years before diagnosis. The 30% relative increase, while consistent, represents a modest absolute shift at the individual level over decades. The appropriate calibration is not alarm but practical prioritization: chronic short sleep in midlife warrants the same routine attention as blood pressure or dietary patterns, because the behavior is modifiable and the signal is consistent.

When a clinical trial announces a "statistically significant" result, the phrase is doing precise mathematical work that has nothing to do with whether the finding matters in practice. Statistical significance, conventionally defined as a p-value below 0.05, is a measure of confidence that an observed effect is unlikely to have occurred by chance alone. P-values address whether an effect exists; they say nothing about the size of the effect, the population it applies to, or whether it is large enough to change a treatment decision.

A trial enrolling 80,000 participants can detect a difference between groups so small it has no practical consequence, and that difference will still be reported as significant. Conversely, an important effect can miss the statistical threshold in an underpowered trial despite representing a clinically meaningful signal. The confusion is structural: drug approval processes, journal publication standards, and media framing all converge on the binary of significant or not. Effect size, the quantity that determines whether a finding should actually change anything, receives far less coverage.

The distinction matters most where baseline risks are low. A 25% relative reduction in a risk that starts at 1 in 1,000 may be statistically significant and clinically trivial for most people who would receive the intervention. When a result is described as significant, the relevant questions are what the absolute numbers show, in which specific population, and how many people would need the intervention for one to benefit. Statistical significance answers whether an observed effect is probably real. Clinical significance answers whether that effect is large enough to matter. A result can satisfy the first standard while falling short of the second, which is why statistically significant findings do not always deserve the headlines they receive. A result that is statistically significant but shows a small absolute effect in a narrowly defined group rarely warrants the headline it receives.

The Claim: Across social media and supplement marketing, berberine, a plant-derived compound, has been framed as a natural alternative to prescription GLP-1 receptor agonists such as Ozempic, with claims of comparable weight loss and metabolic benefit.

The Distortion: Clinical trials show berberine produces weight reductions of roughly 2 to 7 pounds (1 to 3 kilograms) over 8 to 12 weeks. Prescription GLP-1 receptor agonists achieve approximately 10% or more of body weight. Most berberine trials enrolled fewer than 100 participants and measured glucose or lipid markers rather than weight as a primary outcome. No head-to-head comparison against a GLP-1 drug has been conducted.

The Calibration: Berberine has modest, plausible effects on glucose regulation and lipid profiles worth studying on their own terms. Equivalence to prescription GLP-1 drugs is marketing, not evidence.

The Claim: Following regulatory clearance of over-the-counter continuous glucose monitors (such as Dexcom Stelo and Abbott Lingo) in 2024, these devices have been marketed to healthy adults without diabetes as tools for metabolic optimization and performance enhancement.

The Distortion: Regulatory clearance reflects a safety determination, not an efficacy one. No large randomised controlled trial has demonstrated that continuous glucose monitoring in otherwise healthy adults without diabetes improves health outcomes. The glucose fluctuations these monitors capture in metabolically healthy individuals are generally within normal physiological ranges; the clinical significance of optimizing around them is unestablished.

The Calibration: For adults with diagnosed diabetes or prediabetes, the evidence for continuous glucose monitoring is far stronger. For metabolically healthy adults using these devices for wellness purposes, meaningful health benefits have not yet been demonstrated in large randomised controlled trials. This is an absence of evidence - not evidence that the devices cannot be useful. Current marketing claims, however, extend well beyond what the research currently shows.

Stay calibrated.

If The Calibration brought you a clearer perspective today, forward it to someone who values the same.

Received this from a friend or colleague? Subscribe here to get it directly.

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 2023.

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine, 2024.

Association Between Ultraprocessed Food Consumption and Cardiovascular Disease Risk. Journal of the American College of Cardiology: Advances, 2026.

Association Of Sleep Duration In Middle And Old Age With Incidence Of Dementia. Nature Communications, 2021.

Statistical Significance Versus Clinical Importance of Observed Effect Sizes: What Do P Values and Confidence Intervals Really Represent? Anesthesia & Analgesia, 2018.

The Calibration is an editorially curated health briefing. Content is drawn from published research and credible sources for informational purposes only. It does not constitute medical advice, clinical guidance, diagnosis, or treatment, and is not a substitute for consultation with a qualified healthcare professional. Nothing in this briefing should be used to make health or treatment decisions or to delay seeking professional medical advice.

Sponsored content, when present, will always be clearly identified.